Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.

A man who abused five cats in the Ang Mo Kio township of Singapore killing two by throwing them off public housing blocks, ...

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

“Many people with high-function depression are chasing goals that are mostly materialistic, like getting an accolade or ...

Investing.com -- Shares of Neurocrine (NASDAQ: NBIX) Biosciences (NASDAQ: NBIX) tumbled 11% as the company reported revenues that fell short of estimates. Despite reporting a 26% growth in INGREZZA® ...

Outside of stroke, tDCS has had major setbacks in recent years. The DepressionDC study found it to be no better than sham as ...

Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its ...

Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma.

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

The prosecution had sought a jail term of 24 months but the judge said he found this "somewhat excessive". Read more at ...

The Company has also granted to the underwriter a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price per share, less underwriter discounts and ...

SINGAPORE: A man who vented his frustrations by abusing cats and killed two felines by throwing them off high floors at ...